Wir sind mit live!
Mehr erfahren
Anebulo Pharmaceuticals
Nicht mehr börsennotiert
ANEB wurde am 27. Februar 2026 von der Börse genommen.
Profil: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Mitarbeiter: 3
Nachrichten
Positiv
Neutral
Negativ
Stimmung
3 Monate
Positiv
0 %
Neutral
0 %
Negativ
0 %
Kursdiagramme mit Lightweight Charts™ umgesetzt